scholarly journals Comparison and Prognostic Analysis of Adjuvant Radiotherapy versus Salvage Radiotherapy for Treatment of Radically Resected Locally Advanced Esophageal Squamous Cell Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Xin Xu ◽  
Hua-Ying Xie ◽  
Di Zhou ◽  
Ren-Hua Huang ◽  
Yong-Rui Bai ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Adjuvant Radiotherapy ◽  
Locally Advanced ◽  
Radical Resection ◽  
Salvage Radiotherapy ◽  
Radiotherapy Group

Objective. To compare adjuvant radiotherapy and salvage radiotherapy after radical resection for treatment of esophageal squamous cell carcinoma (ESCC).Methods. Data from 155 patients with locally advanced ESCC who underwent radical resection and received postoperative radiotherapy from 2005 to 2011 were reviewed. Seventy-nine patients received adjuvant radiotherapy and 76 received salvage radiotherapy after locoregional recurrence.Results. The median disease-free survival (DFS) and overall survival (OS) were significantly higher in the adjuvant radiotherapy group than the salvage radiotherapy group (DFS 25.73 months versus 10.73 months,P<0.001; OS 33.33 months versus 26.22 months,P=0.006). The independent prognostic factors for DFS were performance status (PS) before radiotherapy and pathological stage in the adjuvant radiotherapy group, compared with lymph node metastasis, tumor location, and adjuvant chemotherapy in the salvage radiotherapy group. The independent prognostic factors for OS were age and PS in both groups. No differences in median DFS and OS between the groups were observed in patients aged > 65 years or with PS ≥ 2.Conclusion. Compared to salvage radiotherapy, postoperative adjuvant radiotherapy can prolong DFS and OS for patients with radically resected local advanced ESCC but cannot improve survival for patients aged > 65 years or with PS ≥ 2.

scholarly journals Whole-Course Conformal Radiotherapy Combined with Late-Course Accelerated Hyperfractionation Radiotherapy for Esophageal Squamous Cell Carcinoma: A Report of 110 Cases

2021 ◽  
Author(s):  
jianyong sun ◽  
weiju huang ◽  
jingbin chen ◽  
yaohong zhang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Local Control ◽  
Squamous Cell ◽  
Failure Modes ◽  
Survival Rates ◽  
Conformal Radiotherapy ◽  
Radiotherapy Group

Abstract Purpose: This retrospective study was designed to analyze the effect and prognostic factors of whole-course conformal radiotherapy and late-course accelerated hyperfractionation radiotherapy (LCAFRT) for esophageal squamous cell carcinoma (ESCC).Methods and materials: A total of 110 patients with ESCC received whole-course conformal radiotherapy and LCAFRT in Chaozhou City People’s hospital between May 2004 and January 2015. All patients received conventional conformal radiotherapy of 2 Gy per day up to 30–40 Gy, followed by accelerated hyperfractionation conformal radiotherapy using reduced fields at 1.5 Gy/fraction twice a day up to 24–39 Gy, with a total dose of 60–69 Gy.Results: Median follow-up was 85 months (2–170 months). The one-, three-, and five-year survival rates were 81.82%, 46.36%, and 41.82%, respectively. The median survival time was 31.8 months. The local control rates for the whole group at 1, 3, and 5 years were 82.73%, 70%, and 68.18%, respectively. There were no significant differences among 1-, 3-, and 5-year survival rates and local control rates between the three-dimensional conformal radiotherapy group and intensity-modulated radiotherapy group. The main reactions to acute radiotherapy were acute radiation tracheitis, esophagitis, and pneumonia. Multivariate analysis showed that the tumor location and TNM stage were independent prognostic factors.Conclusion: The results from this study showed that whole-course conformal radiotherapy and LCAFRT for ESCC can further improve survival and local control with a tolerable acute reaction compared to previous studies. Local recurrence and distant metastasis are the main failure modes of treatment.

scholarly journals Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Xi-Lei Zhou ◽  
Chang-Hua Yu ◽  
Wan-Wei Wang ◽  
Fu-Zhi Ji ◽  
Yao-Zu Xiong ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Esophageal Squamous Cell Carcinoma ◽  
Elderly Patients ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Concurrent Chemoradiotherapy ◽  
Response Rate ◽  
Locally Advanced ◽  
Grade 3

Abstract Background This retrospective study was to assess and compare the toxicity and efficacy of concurrent chemoradiotherapy (CCRT) with S-1 or docetaxel and cisplatin in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods Patients with locally advanced ESCC who received CCRT with S-1 (70 mg/m2 twice daily on days 1–14, every 3 weeks for 2 cycles, S-1 group) or docetaxel (25 mg/m2) and cisplatin (25 mg/m2) on day 1 weekly (DP group) between 2014 and 2016 were retrospectively analyzed. Radiotherapy was delivered in 1.8–2.0 Gy per fraction to a total dose of 50–60 Gy. Treatment-related toxicities (Common Terminology Criteria for Adverse Events version 4.0), response rate, and survival outcomes were compared between groups. Results A total of 175 patients were included in this study (72 in the S-1 group and 103 in the DP group). Baseline characteristics were well balanced between the two groups. The incidence of grade 3–4 adverse events were significantly lower in the S-1 group than that of the DP group (22.2% vs. 45.6%, p = 0.002). In the DP group, elderly patients (> 60 years) had a significantly higher rate of grade 3–4 adverse events than younger patients (58.1% vs. 31.3%, p = 0.01). The objective overall response rate (complete response + partial response) was 68.1% in the S-1 group, and 73.8% the DP group (p = 0.497). The 3-year overall survival was 34.7% in the S-1 group, and 38.8% in the DP group (p = 0.422). The 3-year progression free survival in the DP group was higher than that in the S-1 group but without significant difference (33.0% vs. 25.0%, p = 0.275). Conclusion CCRT with S-1 is not inferior to CCRT with docetaxel and cisplatin and is better tolerated in in elderly patients with locally advanced ESCC.

Sign in / Sign up

Export Citation Format

Share Document